Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
Abstract Early intervention is essential for favorable long-term outcomes in schizophrenia. However, there is limited guidance in the scientific literature on how best to choose between dopamine D2 receptor (D2R) partial agonists and D2R antagonists in early stages of schizophrenia. The aim of this...
Guardado en:
Autores principales: | David D. Kim, Alasdair M. Barr, Lulu Lian, Jessica W. Y. Yuen, Diane Fredrikson, William G. Honer, Allen E. Thornton, Ric M. Procyshyn |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c042fb3e4c884481899696710da10319 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aripiprazole for late-life schizophrenia
por: Jeffrey Rado, et al.
Publicado: (2010) -
Oxidative Stress Biomarkers as a Predictor of Stage Illness and Clinical Course of Schizophrenia
por: Dariusz Juchnowicz, et al.
Publicado: (2021) -
Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb N, et al.
Publicado: (2012) -
Personalized medicine for schizophrenia
por: Peter F. Buckley, et al.
Publicado: (2017) -
Aripiprazole-associated tic in a schizophrenia patient
por: Guo X, et al.
Publicado: (2015)